Inotrem has developed a novel immunomodulation concept that targets the TREM-1 pathway to control inflammatory responses. Their proprietary technology platform has led to the creation of the first-in-class TREM-1 inhibitor, nangibotide (LR12), with potential applications in septic shock and myocardial infarction. Additionally, Inotrem is working on a program to address chronic inflammatory diseases. Founded in 2013, the company is based in Paris and has a technology center in Nancy, France.